196 related articles for article (PubMed ID: 25666484)
21. Estrogen-mediated mechanisms to control the growth and apoptosis of breast cancer cells: a translational research success story.
McDaniel RE; Maximov PY; Jordan VC
Vitam Horm; 2013; 93():1-49. PubMed ID: 23810002
[TBL] [Abstract][Full Text] [Related]
22. Targeted Therapies: Treatment Options for Patients With Metastatic Breast Cancer.
Richards R; Keating E; Boucher JE
Clin J Oncol Nurs; 2019 Aug; 23(4):434-438. PubMed ID: 31322617
[TBL] [Abstract][Full Text] [Related]
23. [New developments in hormonal therapy for breast cancer].
Tominaga T
Gan To Kagaku Ryoho; 1996 May; 23(6):678-83. PubMed ID: 8645017
[TBL] [Abstract][Full Text] [Related]
24. Endocrine therapy for the treatment of postmenopausal women with breast cancer.
Harichand-Herdt S; Zelnak A; O'Regan R
Expert Rev Anticancer Ther; 2009 Feb; 9(2):187-98. PubMed ID: 19192957
[TBL] [Abstract][Full Text] [Related]
25. Overcoming endocrine resistance in breast cancer: role of the PI3K and the mTOR pathways.
Provenzano A; Kurian S; Abraham J
Expert Rev Anticancer Ther; 2013 Feb; 13(2):143-7. PubMed ID: 23406555
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant endocrine therapy for premenopausal hormone receptor-positive breast cancer; much done, more to do.
Higgins MJ; Wolf AC
Oncology (Williston Park); 2009 Jan; 23(1):40, 42, 44. PubMed ID: 19283920
[No Abstract] [Full Text] [Related]
27. Optimizing endocrine therapy in premenopausal ER-positive breast cancer patients.
Ruddy KJ; Partridge AJ
Oncology (Williston Park); 2009 Jan; 23(1):34, 40. PubMed ID: 19283919
[No Abstract] [Full Text] [Related]
28. Breast cancer prevention by antihormones and other drugs: where do we stand?
Lazzeroni M; DeCensi A
Hematol Oncol Clin North Am; 2013 Aug; 27(4):657-72, vii. PubMed ID: 23915737
[TBL] [Abstract][Full Text] [Related]
29. [Advancement in endocrine therapy for breast cancer].
Yang MT; Lian ZQ
Ai Zheng; 2007 Apr; 26(4):440-4. PubMed ID: 17430670
[TBL] [Abstract][Full Text] [Related]
30. [Future endocrine therapy of breast cancer].
Ejlertsen B
Ugeskr Laeger; 2007 Jan; 169(4):296. PubMed ID: 17274921
[No Abstract] [Full Text] [Related]
31. Prolonged clinical benefit from the maintenance hormone therapy in patients with metastatic breast cancer.
Lim S; Lee S; Han J; Park BW; Kim S; Park S; Kim JH; Choi HJ; Sohn J
Breast; 2013 Dec; 22(6):1205-9. PubMed ID: 24135766
[TBL] [Abstract][Full Text] [Related]
32. Hormonal therapy for endometriosis: from molecular research to bedside.
Tosti C; Biscione A; Morgante G; Bifulco G; Luisi S; Petraglia F
Eur J Obstet Gynecol Reprod Biol; 2017 Feb; 209():61-66. PubMed ID: 27503693
[TBL] [Abstract][Full Text] [Related]
33. Selecting adjuvant endocrine therapy for breast cancer.
Eneman JD; Wood ME; Muss HB
Oncology (Williston Park); 2004 Dec; 18(14):1733-44, discussion 1744-5, 1748, 1751-4. PubMed ID: 15700624
[TBL] [Abstract][Full Text] [Related]
34. [Long-term results of adjuvant endocrine therapy for hormone receptor-positive breast cancer].
Semilgazov VF; Manikhas AG; Semiglazov VV; Bozhok AA; Dashian GA; Ivanov VG; Paltuev RM; Vasil'ev AG; Shchedrin DE; Ermachenkova AM; Nikitina IV; Pen'kov KD; Bessonov AA; Tabagua TT; Kolar'kova VV
Vopr Onkol; 2011; 57(5):567-77. PubMed ID: 22238925
[No Abstract] [Full Text] [Related]
35. Expanding role of ovarian suppression/ablation in premenopausal ER-positive breast cancer: issues and opportunities.
Schem C; Jonat W
Oncology (Williston Park); 2009 Jan; 23(1):44, 47. PubMed ID: 19283921
[No Abstract] [Full Text] [Related]
36. The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2.
Prat A; Baselga J
Nat Clin Pract Oncol; 2008 Sep; 5(9):531-42. PubMed ID: 18607391
[TBL] [Abstract][Full Text] [Related]
37. Sex hormone receptors in breast cancer.
D'Abreo N; Hindenburg AA
Vitam Horm; 2013; 93():99-133. PubMed ID: 23810004
[TBL] [Abstract][Full Text] [Related]
38. Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases.
El-Saghir NS; El-Hajj II; Makarem JA; Otrock ZK
Anticancer Drugs; 2006 Sep; 17(8):999-1002. PubMed ID: 16940812
[TBL] [Abstract][Full Text] [Related]
39. Selective Androgen Receptor Modulator in a Patient With Hormone-Positive Metastatic Breast Cancer.
Vontela N; Koduri V; Schwartzberg LS; Vidal GA
J Natl Compr Canc Netw; 2017 Mar; 15(3):284-287. PubMed ID: 28275030
[TBL] [Abstract][Full Text] [Related]
40. Optimal adjuvant endocrine therapy for early breast cancer.
Stuart-Harris R; Davis A
Womens Health (Lond); 2010 May; 6(3):383-98. PubMed ID: 20426605
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
